Healthcare Oct 19, 2021 10:21 AM (GMT+8) · EqualOcean
19, the European health center was informed today that the latest announcement by the China National Drug Administration (NMPA) that the new class of microorganism 1 new drugs, Western glipetna, has been approved for sale. The single drug is suitable for diet control and exercise to improve blood glucose control in adults with type 2 diabetes. Ciglitazar sodium is a total agonist of peroxisome proliferator activated receptor (PPAR), which can activate three subtype receptors of PPAR at the same time( α、γ and δ), It also induced the expression of downstream target genes related to insulin sensitivity, fatty acid oxidation, energy conversion and lipid transport, and inhibited PPAR related to insulin resistance γ Phosphorylation of the receptor provides a new therapeutic option for adults with type 2 diabetes. It is reported that ciglitazidine sodium is a new generation of insulin sensitizer candidate drug independently designed, synthesized, screened and developed by microchip biology. It is also the second approved new drug after sidabelamine.